Feed GSK
GS

GSK

GSK · NYSE

$50.31 +0.60% (+$0.30)
1M -2.23%
Market Cap £75.3B
P/E Ratio 15.62x
Div. Yield 3.62%
ROE 24.36%

Bulios Fair Price

$50.82

1.0% upside

Trenutna cena

$50.31

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price se delnica GSK trenutno trguje blizu svoje poštene vrednosti. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
8/9
Valuation
84 /100
Cheap
EV/EBITDA 8.31x
P/S 2.27x
P/B 4.29x
Growth
25 /100
Declining
Rev. growth 3.66%
FCF growth 4.81%
Book val. growth 15.54%
Profitability
93 /100
Strong
Net margin 14.52%
Op. margin 20.70%
FCF margin 21.02%
Quality
77 /100
Excellent
ROE 24.36%
ROA 7.86%
Asset turnover 0.54x
Debt
63 /100
Moderate
Current ratio 0.82x
Int. coverage 9.56x
Net debt/EBITDA 1.38x
Stability
51 /100
Moderate
Rev. volatility 0.39%
EPS volatility 234.69%
Profitable years 6

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o GSK
Online

O podjetju

GSK plc is a global pharmaceutical company with a long history and a wide portfolio of medicinal products. The company specializes in researching, developing, and manufacturing drugs for various therapeutic areas, including infectious diseases, respiratory conditions, oncology, immunology, and others. GSK is known for its iconic products and vaccines that help fight diseases worldwide. The company collaborates with research institutions and partners around the world to innovate in the field of medicines and provide new and effective treatment solutions. GSK is also actively working on the development of new vaccines and drugs, including vaccines for COVID-19. GSK plc (GSK) shares may be an interesting choice for investors who follow the pharmaceutical industry and seek investment opportunities in a long-established company with innovative research and a wide portfolio of medicinal products.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Luke Victor Miels

Employees

66,841

Headquarters

London

Prihajajoči dogodki

28 OKT.

Earnings

Upcoming earnings report

41d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.